Company Established in 2003, Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess cardiovascular risk and risk of diabetes. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader - a state of art diagnostic device which can determine the tissue accumulation of AGEs in 12 seconds. AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The amount of AGEs in tissue serves as an important cardiovascular risk predictor. The AGE Reader measurements allows the doctor to adjust the treatment for high-risk patients as soon as possible.